EXTON, Pa., March 14 /PRNewswire-FirstCall/ -- Isolagen(TM), Inc. today announced that the Company’s Vice President and Corporate Controller, Todd Greenspan, has been promoted to Chief Financial Officer (CFO) and John Maslowski has been promoted to Vice President of Operations.
In addition to the accounting, financial planning, budgeting and reporting responsibilities, Todd Greenspan will oversee the human resources, information technology and legal functions. Todd will continue to report to Chief Executive Officer Declan Daly and serve as a member of the executive leadership team.
“The Board of Directors and I are very pleased to promote Todd to CFO,” said Declan Daly, Chief Executive Officer of Isolagen, Inc. “Todd has demonstrated a wide range of high-level fiscal and budgetary expertise since he joined Isolagen as Corporate Controller in 2005. He has also shown strong loyalty and commitment to the Company. Todd has proven himself to be well qualified for this job and I have no doubt that he will be an excellent CFO.”
Mr. Greenspan joined Isolagen in 2005 as Corporate Controller and was previously promoted to Vice President of Finance. Prior to joining Isolagen, Mr. Greenspan served in financial roles of increasing responsibility, including having served as Senior Director of Finance for Amkor Technology, Inc. from 2002 to 2005. Mr. Greenspan is a licensed certified public accountant in the state of Pennsylvania and obtained both his BS in Accounting and Master’s degree in Accounting and Management Information Services (MIS) from the University of Delaware.
Isolagen Promotes John Maslowski to Vice President of Operations
Isolagen also announced the promotion of Senior Director of Operations, John Maslowski, to the position of Vice President of Operations. John will report to Chief Executive Officer Declan Daly and serve as a member of the executive leadership team.
“John’s promotion is very well deserved,” said Mr. Daly. “He has overseen significant improvement in our Manufacturing and Process Development areas. His manufacturing and quality experience, combined with his commitment, make him ideal to head our Operations group.”
Mr. Maslowski joined Isolagen in 2005 and has since held various management positions in Manufacturing and Quality Assurance with the Company. Prior to Isolagen, Mr. Maslowski was employed at Wyeth Pharmaceuticals from 2001 to 2005, serving most recently as Quality Assurance Investigations Manager in support of manufacturing. Previously, Mr. Maslowski held positions with Merck Research Laboratories and Teva Pharmaceuticals. Mr. Maslowski holds a BS in Biology from Ursinus College and MS in Biology from Villanova University. In addition, he is a Certified Quality Auditor through the American Society for Quality.
“I am confident that our new executive leadership team is well equipped to drive the Company during this important time,” concluded Mr. Daly.
About Isolagen, Inc.
Isolagen(TM), Inc. is an aesthetic and therapeutic company committed to developing and commercializing scientific advances and innovative technologies. The company’s technology platform includes the Isolagen Process(TM), a cell processing system for skin and tissue rejuvenation which is currently in clinical development for a broad range of aesthetic and therapeutic applications including wrinkles, acne scars, burns and periodontal disease. Isolagen also commercializes a scientifically-advanced line of skincare systems through its majority-owned subsidiary, Agera(R) Laboratories, Inc. For additional information, please visit www.isolagen.com .
Isolagen Forward Looking Statements
All statements in this news release that are not based on historical fact are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of our control, that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under Item 1A “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2007, as updated in “Item 1A. Risk Factors” in the Company’s Quarterly Reports on Form 10-Q filed since the annual report. We operate in a highly competitive and rapidly changing environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise any forward- looking statements. Readers are also urged to carefully review and consider the other various disclosures in the Company’s Annual Report on Form 10-K for the year ended December 31, 2007, as well as other public filings with the SEC since such date.
CONTACT: Mike Beyer of Sam Brown Inc., +1-773-463-4211,
beyer@sambrown.com, for Isolagen, Inc.
Web site: http://www.isolagen.com/
